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ABSTRACT
Introduction Exercise is emerging as a therapy in 
oncology for its physical and psychosocial benefits 
and potential effects on chemotherapy tolerability and 
efficacy. However, evidence from randomised controlled 
trials (RCTs) supporting exercise in patients with 
borderline resectable or locally advanced pancreatic 
cancer (PanCa) undergoing neoadjuvant therapy (NAT) are 
lacking.
Methods and analysis The EXPAN trial is a dual- centre, 
two- armed, phase I RCT. Forty patients with borderline 
resectable or locally advanced PanCa undergoing NAT 
will be randomised equally to an exercise intervention 
group (individualised exercise+standard NAT) or a 
usual care control group (standard NAT). The exercise 
intervention will be supervised and consist of moderate to 
vigorous intensity resistance and aerobic- based training 
undertaken two times a week for 45–60 min per session 
for a maximum period of 6 months. The primary outcome 
is feasibility. Secondary outcomes are patient- related 
and treatment- related endpoints, objectively measured 
physical function, body composition, psychological health 
and quality of life. Assessments will be conducted at 
baseline, prior to potential alteration of treatment (~4 
months postbaseline), at completion of the intervention 
(maximum 6 months postbaseline) and 3- month and 
6- month postintervention (maximum 9 and 12 months 
postbaseline).
Ethics and dissemination The EXPAN trial has been 
approved by Edith Cowan University (reference no.: 2020-
02011- LUO), Sir Charles Gairdner Hospital (reference 
no.: RGS 03956) and St John of God Subiaco Hospital 
(reference no.: 1726). The study results will be presented 
at national/international conferences and submitted for 
publications in peer- reviewed journals.
Trial registration number ACTRN12620001081909.
INTRODUCTION
Advances in neoadjuvant therapy (NAT) and 
surgical techniques for pancreatic cancer 
(PanCa) have improved the likelihood of 
patients with borderline resectable or locally 
advanced disease undergoing curative- intent 
surgery.1 2 However, rates of operability and 
margin- negative (R0) resection remain low 
for patients with borderline resectable (oper-
ability: 69%, R0: 54%) or locally advanced 
(operability: 26%, R0: 23%) PanCa after 
NAT (based on various pre- NAT resectability 
criteria)3 due to poor response to current 
regimens. This may be due to the complex 
microenvironment of PanCa characterised 
by a high percentage of tumour stroma that 
leads to dysfunction in nearby blood vessels 
and impedes drug delivery to tumour cells.4 
In addition, dose reductions, dose delays and 
reduced relative dose intensity (RDI) are 
common in these patients during NAT due 
to dose- limiting toxicities (such as fatigue, 
neutropenia, vomiting and diarrhoea),5 6 
which can also contribute to reduced thera-
peutic response.7
Patient physical condition is an important 
consideration before proceeding to PanCa 
surgery.2 8 However, patients with PanCa 
are relatively older (median age 71 years)2 
and are at high risk of developing debili-
tating syndromes including sarcopaenia and 
cachexia.9 These factors along with cumula-
tive toxicities of NAT can worsen patients’ 
preoperative condition and, in turn, increase 
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risk of complications and prolonged recovery after 
surgical resection, ultimately impairing their long- term 
survival.10 11 Further, side effects relating to PanCa and 
its treatments have a negative impact on patients’ psycho-
logical health and quality of life (QoL).12 13 Given the 
suboptimal responses to current NAT and the extensive 
treatment- related side effects in patients with border-
line resectable or locally advanced PanCa, research into 
interventions to address these unmet needs is of clinical 
importance.
Exercise has been recommended as an effective therapy 
for persons following a cancer diagnosis in managing 
fatigue, psychological distress, muscle loss and declines 
in physical function and QoL.14 15 Of importance, there 
is early evidence suggesting that exercise may serve as 
a potential strategy to improve chemotherapy tolera-
bility.16 17 Further, preclinical and clinical trials (including 
a trial in patients with PanCa) suggest that exercise 
normalises tumour vasculature, which in turn may lead 
to augmented efficacy of chemotherapy via increasing 
drug delivery.18–21 Despite the benefits associated with 
exercise in cancer management, only seven exercise trials 
have been undertaken in patients with PanCa with over 
half being case reports or a case series.22–24 Although a 
recent systematic review by our team found that exer-
cise may be safe and feasible in patients with PanCa,24 
most of the patients enrolled in the studies were highly 
selected having already successfully completed NAT and 
surgical resection. Additionally, a case series25 and a case 
report26 of patients with borderline resectable or locally 
advanced PanCa during NAT performing supervised 
exercise training showed promising results that warrant 
further investigation with a more rigorous study design. 
Therefore, we propose to undertake a pilot randomised 
controlled trial (RCT) to examine the feasibility and 
efficacy of a supervised, multicomponent exercise 
programme in patients with borderline resectable or 
locally advanced PanCa undergoing NAT.
METHODS AND ANALYSIS
In this manuscript, we describe the rationale and design 
considerations of the EXPAN trial. The protocol was 
developed and reported according to the SPIRIT (Stan-
dard Protocol Items: Recommendations for Interven-
tional Trials) guidelines.27
Study design
The study design and a schematic schedule for enrol-
ment, intervention and assessments of the EXPAN trial 
is outlined in figures 1 and 2, respectively. The EXPAN 
trial is a dual- centre, two- armed, phase I RCT to examine 
the feasibility and efficacy of a supervised, multicom-
ponent exercise medicine programme in patients with 
borderline resectable or locally advanced PanCa under-
going NAT. Following completion of eligibility screening, 
informed consent and baseline assessment, recruited 
patients will be randomised equally to an intervention 
group (individualised exercise training concomitant 
with standard NAT) or a usual care control group (stan-
dard NAT). Participants will undergo additional assess-
ments at completion of the intervention (maximum 6 
months postbaseline), 3- month and 6- month postinter-
vention (maximum 9 and 12 months postbaseline). For 
participants who will undergo additional chemotherapy 
with or without radiation (including CyberKnife) after 
induction chemotherapy, a midpoint assessment will be 
performed before the alteration of treatment (~4 months 
postbaseline).
Eligibility criteria
Men and women diagnosed with borderline resectable 
or locally advanced pancreatic ductal adenocarcinoma as 
per the Australasian Gastro- Intestinal Trials Group defini-
tion (AGITG)28 will be invited to participate in the study. 
Major inclusion and exclusion criteria are as follows:
Inclusion criteria
1. Age ≥18 years.
2. Waiting to start or within 4 weeks after starting their 
prescribed neoadjuvant chemotherapy with or without 
locoregional radiotherapy.
3. Approved by their treating oncologist to participate in 
the trial.
Exclusion criteria
1. Recurrent PanCa with or without exposure to previous 
chemotherapy.
2. Having undergone treatments for another primary 
cancer within the last 12 months, or another ongoing 
active primary malignancy.
3. Anticipating undergoing major surgery for non- cancer 
diseases within the next 6 months.
4. Any musculoskeletal, cardiovascular or neurological 
disorder that could put them at risk during exercise 
testing and training.
5. Having participated in planned, individualised and 
supervised exercise training for ≥2 days/week in the 
previous month.
6. Unable to travel to any designated training and/or 
testing site.
Sample size
Given the pilot nature of the EXPAN trial investigating 
primarily the safety and feasibility of the exercise inter-
vention in patients with PanCa during NAT, no formal 
sample size calculation was performed a priori. However, 
according to the study clinicians, the number of partici-
pants that is viable over a 12- month recruitment period 
in the participating hospitals would be approximately 
40 (ie, 20 per group). This has been reported to be an 
acceptable sample size for a pilot RCT (ie, 12–35 persons 
per group).29–31
Recruitment
The EXPAN trial will receive support for recruitment from 
the Multidisciplinary Team in Upper Gastrointestinal 
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Cancers at Sir Charles Gairdner Hospital (SCGH) and 
St John of God Subiaco Hospital (SJOGSH). Partici-
pants will be recruited using the following methods: (1) 
The study investigator reviews electronic clinical notes 
at SJOGSH every 2 weeks to initially identify potential 
participants. Subsequently, the attending oncologist or 
clinical nurse is asked for confirmation of their clinical 
eligibility and permission to contact. (2) The attending 
oncologists or clinical nurses at both hospitals identify 
clinically eligible patients and inform them about the 
study. Should patients express an interest in the study 
and provide permission, their contact details will be 
passed to the study investigator. On obtaining permis-
sion to contact potential participants in either way, the 
investigator will approach them by telephone to discuss 
all aspects involved with the study and perform eligibility 
screening. Patients who meet the eligibility criteria and 
are interested in the study will then be invited to partici-
pate and will be provided with a set of recruitment docu-
ments and questionnaires via post, email, fax or Microsoft 
Forms (for questionnaires) as appropriate. They will be 
advised to provide written informed consent before the 
baseline assessment.
In addition, participants will be recruited through 
advertisement posting on the website of the Exercise 
Medicine Research Institute (EMRI) at Edith Cowan 
University (ECU). Interested patients can contact the 
study investigator via phone or email for further informa-
tion regarding the EXPAN trial.
Randomisation and blinding
After completion of the baseline assessment, participants 
will be randomly allocated on a 1:1 basis to an exercise 
intervention group or a usual care control group using 
a random allocation sequence generated by a secure 
website, Sealed Envelope (London, UK).32 The rando-
misation will be stratified by participants’ disease stage 
(borderline resectable vs locally advanced) and age (<65 
years vs ≥65 years) to account for variations in historical 
operability rate following standard NAT in the hospitals. 
Random permuted blocks (block size 2 and 4) will be 
employed to ensure balanced allocation of participants 
Figure 1 Flowchart of study design. *Only for participants who are unresectable and will undergo additional chemotherapy 
with or without radiation (including CyberKnife) after induction chemotherapy. CTx, chemotherapy; Ex, exercise intervention; 
NAT, neoadjuvant therapy; RTx, radiotherapy.
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into both groups. Assessors of the efficacy outcomes 
and participants’ treating oncologists will be blinded to 
group allocation. Due to the nature of the exercise inter-
vention, participants will not be blinded to intervention 
assignment following randomisation. However, they will 
be required not to reveal their group allocation to the 
assessors and their treating oncologists.
Intervention
An overview of the exercise intervention is provided in 
table 1. The exercise program is scheduled for a maximum 
period of 6 months, which will be terminated prior to 
potential surgical resection. Participants in the intervention 
group will undertake individually tailored exercise training 
in any of the three ECU affiliated exercise clinics/facilities 
that covers different areas of the city. They will be required 
to exercise at a frequency of two sessions per week with 
45–60 min/session (including a 5 min warm- up and cool- 
down). In each session, participants will perform 20–30 min 
of resistance training and a maximum 20 min of aerobic- 
based exercise (continuous cycling or intermittent sport- 
related activities). All the prescribed exercise components 
in a session will be performed in a one- to- one fashion or in 
a small group depending on participants' training schedule 
or availability and closely supervised by the investigator. The 
exercise programme will follow the principle of progres-
sive overload and autoregulated based on a participant’s 
perceived readiness for training at the start of an exercise 
session. Given that participants will be exercising during 
NAT, a flexible training schedule will be adopted to accom-
modate individual treatment schedule. In addition, partici-
pants who are absent from a session will be followed up via 
phone and encouraged to make up for a missed session 
anytime in the same week (ie, during daytime on weekdays 
and weekends).
Resistance training
Resistance training will involve 4–6 exercises that cover the 
major muscle groups of the upper- body and lower- body 
using machines and dumbbells (such as overhead press, latis-
simus pull- down, chest press, seated row, leg press and leg 
curl). For each exercise, participants will perform 1–3 sets 
at 8–12 repetition maximum with 60 s recovery between sets. 
The weight will be increased by 5%–10% when a participant 
can successfully complete two additional repetitions on the 
last set of an exercise for two consecutive sessions.33 A similar 
resistance training regimen has been tested and shown to be 
acceptable in patients following PanCa surgery.34
Aerobic-based exercises
In addition to resistance training, each session includes a 
maximum of 20 min of either continuous cycle ergometer 
exercise or intermittent sport- related activities (such as 
repeated punches thrown and agility ladder drills), which 
Figure 2 SPIRIT schematic schedule of enrolment, interventions and assessments for the EXPAN trial. ●: fixed assessment 
time points; ○: potential assessment time point. *Only for the intervention group. †Measured in line with routine clinical 
examination of the hospitals with the data collected closest to the predefined assessment time points (ie, Tm, T1 and T3) 
used for the EXPAN trial. ‡Only for participants receiving pancreatic cancer surgery. BSI-18, Brief Symptom Inventory-18; 
DXA, dual X- ray absorptiometry; EORTC QLQ, European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire; GSLTPAQ, The Godin- Shephard leisure- time physical activity questionnaire; 1 RM, 1- repetition maximum; 
PACES, physical activity enjoyment scale; RADL, resumption of activities of daily living; RPE, the rating of perceived exertion 
(the 10- point Borg Scale); T0, baseline; Tm, potential midpoint (~4 months postbaseline); T1, at completion of the exercise 
intervention (maximum 6 months postbaseline); T2, 3 months after T1 (maximum 9 months postbaseline); T3, 6 months after T1 
(maximum 12 months postbaseline).
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will be alternated from session to session to provide greater 
variety and training stimulus. Exercise intensity will be 
manipulated from ~65% to 80% of estimated maximum 
heart rate (MHR) (MHR=220- age), corresponding to a 
rating of perceived exertion (RPE) of 4–6 (Moderate to 
Hard) on the 10- point Borg Category- ratio scale.35 For 
continuous cycling, participants will be required to pedal 
at a cadence of 50–80 rpm.36 The pedalling resistance and 
speed will be progressed to elicit the target heart rate zone 
or RPE. With regard to the intermittent component, 3–8 
bouts of 30–60 s sport- related drills will be performed with 
60 s rest intervals between adjacent bouts. A similar work- 
to- rest ratio has been administrated in patients with cancer 
undergoing chemotherapy.37
Controls
After completion of the baseline assessment and rando-
misation, the study investigator will advise the controls 
to maintain their usual activities. No exercise prescrip-
tions or recommendations will be provided to them. To 
capture information concerning leisure- time exercise 
undertaken incidentally in the controls, a pre- established 
physical activity log will be provided to them. In addition, 
the study investigator will contact the controls via phone 
once per month to facilitate data collection relating to 
incidental exercise, potential adverse events (AEs) and 
any changes in cancer treatment.
Treatment of exocrine pancreatic insufficiency
All study participants will be prescribed Creon (pancre-
lipase delayed- release capsules) for the treatment of 




1. Incidence and severity of AEs (defined as unfavour-
able responses to exercise and NAT undertaken as 
part of the EXPAN trial but may not necessarily be 
related to these treatments) will be tracked by the 
Table 1 Overview of the exercise programme
Length of exercise 
program Maximum 6 months
Setting Edith Cowan University affiliated exercise clinics/facilities
Frequency 2 sessions per week
Session duration 45–60 min (including 5 min warm- up and cool- down)
Warm- up Low- intensity aerobic exercise (eg, treadmill walking)
Cool- down Static stretching
Resistance training
Exercises Overhead press, latissimus pull- down, chest press, seated row, leg press and leg curl
Equipment Weight machines and dumbbells
Duration 20–30 min/session
Number of sets 1–2 (weeks 1–4), 3 (weeks 5 onwards)
Number of repetitions 12 RM (weeks 1–8), 10 RM (weeks 9–16), 8 RM (weeks 17 onwards)
Recovery between sets 60 s
Progression 5%–10% weight increase following the 2- for-2 rule*
Aerobic- based exercises†
Exercises Continuous cycling or intermittent sport- related activities (eg, repeated punches thrown and agility 
ladder drills)
Equipment Continuous: upright or recumbent cycle ergometer
Intermittent: punching bag/pad, gloves and agility ladder
Duration ≤20 min/session
Volume Continuous: 5–10 min (weeks 1–8), 15 min (weeks 9–16), 20 min (weeks 17 onwards)
Intermittent: 3–5 bouts×30 s with 60 s recovery (weeks 1–4), 6–8 bouts×45 s with 60 s recovery (weeks 
5–8), 8 bouts×60 s with 60 s recovery (weeks 9 onwards)
Intensity ~65%–80% of estimated MHR or RPE 4–6
Progression Continuous: increases in resistance and pedalling speed
Intermittent: variations in activity profile and work- to- rest ratio (ie, from 1:2 to 1:1)
*Increasing weight when two additional repetitions on the last set of an exercise can be successfully completed for two consecutive 
sessions.
†Aerobic- based exercise will be alternated from session to session, that is, either continuous cycling or intermittent sport- related activities 
will be performed in a session.
MHR, maximum heart rate; NAT, neoadjuvant therapy; RM, repetition maximum; RPE, rating of perceived exertion (the 10- point Borg Scale).
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study investigator and participants, and identified 
through review of medical records. Specifically, the 
occurrence of AEs during and following an exer-
cise session will be captured by the study investiga-
tor or participants using a pre- established tracking 
log. Any NAT- related AEs will be actively monitored 
by clinicians and obtained via medical records after 
completion of the intervention. The severity of AEs 
will be graded using the National Cancer Institute’s 
Common Terminology Criteria for Adverse Events 
(CTCAE, V.5.0).38
2. Eligibility rate will be calculated by dividing the num-
ber of eligible patients by the number of patients 
screened; recruitment rate will be calculated by the 
number of enrolled patients versus the number of eli-
gible patients. We will assess eligibility and recruitment 
rate at baseline. The number of excluded and unen-
rolled patients will be documented along with the rel-
evant reasons by the study investigator.
3. Attrition rate will be determined by the number of 
dropouts in each group versus the number originally 
allocated and assessed prior to the potential alteration 
of treatment and at completion of the exercise inter-
vention. Reasons for dropping out will be documented 
by the study investigator.
4. Attendance rate will be determined by the total and 
weekly number of exercise sessions attended versus 
the number of sessions prescribed (only for the inter-
vention group). Reasons for non- attendance will be 
documented by the study investigator.
5. Adherence rate will be determined by the number of 
sessions where the prescribed resistance and aerobic- 
based exercises are successfully completed (including 
volume and intensity) versus the number of sessions 
attended (only for the intervention group). A combi-
nation of exercise heart rate (tracked by Polar H10), 
RPE (10- point Borg scale) and duration will be used 
to monitor activity profile for aerobic- based exercises. 
Adherence to resistance training will be assessed by 
calculating the amount of exercise actually complet-
ed (ie, the number of exercises, sets, repetitions and 
weights) and comparing to the individual prescribed 
exercise in each session.39 Reasons for non- adherence 
to an exercise prescription will be documented by the 
study investigator.
Secondary outcomes
Patient-related and treatment-related endpoints
1. Rates of operability and R0 resection will be evaluated 
in line with routine clinical examinations at the hos-
pitals with the latest data collected prior to potential 
alteration of treatment and at completion of the exer-
cise intervention used for the EXPAN trial. Operability 
rate refers to the proportion of participants who 
achieve anatomical resectability status as defined by 
the AGITG28 and proceed to PanCa surgery; R0 re-
section rate is defined as proportion of participants 
who undergo tumour resection with a clear margin 
(>1 mm). The data will be extracted from participants’ 
medical records.
2. Progression- free survival (PFS) will be assessed in line 
with routine clinical examinations at the hospitals with 
the latest data collected prior to potential alteration of 
treatment, at completion of the exercise intervention 
and 6 months post the exercise intervention used for 
the EXPAN trial. In this study, PFS is defined as the 
length of time elapsed from the start of the exercise 
intervention/postrandomisation to an indication of 
disease progression or death from any cause. The data 
will be obtained via participants’ medical records.
3. Chemotherapy RDI will be examined prior to poten-
tial alteration of treatment and at completion of the 
exercise intervention. RDI is determined by the ratio 
of actually delivered dose (mg/m2/week) against the 
planned dose (mg/m2/week) of a regimen. For partic-
ipants receiving a multiple- drug regimen, the RDI for 
each drug and average RDI across all drugs included 
in the regimen will be calculated. The data will be ex-
tracted from participants’ medical records along with 
any documented reasons for regimen delay, change 
and discontinuation.
4. Length of hospital stay (LOS) will be assessed in line 
with routine clinical examinations at the hospitals in 
participants who receive PanCa surgery. In this study, 
LOS is defined as the duration of a single episode of 
hospitalisation between the day completing surgical 
resection and the day being discharged from the hos-
pital. The data will be obtained through participants’ 
medical records at 6 months post the exercise inter-
vention.
5. The incidence and severity of postsurgery complica-
tions will be assessed in line with routine clinical exam-
inations at the hospitals in participants who undertake 
PanCa surgery. We will use the Clavien- Dindo classi-
fication to define and grade the severity of surgical 
complications.40 The data will be obtained via partic-
ipants’ medical records at 6 months post the exercise 
intervention.
6. Resumption of activities of daily living in participants 
following surgical resection will be assessed at 3- month 
and 6- month postexercise intervention using a self- 
administrated questionnaire. The questionnaire is a 
12- item Likert- scale used to rate the degree to which 
the participants have resumed their usual activities of 
daily living.41
Physical function
Physical function will be measured at baseline, prior to 
potential alteration of treatment, and at completion of 
the exercise intervention using a battery of standard tests 
that are as follows:
1. One- repetition maximum (1RM) chest press and leg 
press test is performed to assess muscle strength of 
major muscle groups in the upper- body and lower- 
body, respectively.42 The chest press test is conducted 
on a Cybex chest press machine (Cybex International, 
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Medway, Massachusetts, USA) and leg press on a 
Cybex leg press machine. Following a general warm- 
up, participants undertake two specific warm- up sets of 
eight and three repetitions at approximately 50% and 
70% of an estimated 1 RM, respectively. Subsequently, 
single repetitions are performed with progressively 
heavier weights until failure. The final weight lifted 
successfully is recorded for analysis. To avoid unneces-
sary fatigue, three to five trials are attempted and a rest 
interval of 1–2 min is given between trials.
2. Repeated chair rise test is used to evaluate lower- limb 
muscle function.43 To perform the test, participants sit 
on a hard- backed chair (seat height 43 cm from the 
floor) with their arms folded across their chest. They 
are instructed to rise as fast as possible to a full stand-
ing position and then return to a full sitting position 
five times. Three trials are performed with a 1 min re-
covery between trials. The fastest time recorded will be 
used in the analysis.
3. Four hundred metre walk test is administrated to 
measure cardiorespiratory fitness and walking endur-
ance.43 The test requires participants to walk 400 m 
in a hallway back and forth on a 20 m course as fast as 
possible. The time taken to complete the 400 m walk 
will be used in the analysis.
4. Six- metre backwards tandem walk is undertaken to ex-
amine dynamic balance.44 Participants are required to 
walk backwards in tandem stance (ie, placing one foot 
directly behind the heel of the other with the shoes 
touching) for a distance of 6 m. The time taken to 
complete the distance is recorded for analysis.
Body composition and anthropometry
Whole body lean mass, fat mass and percentage body fat 
will be assessed at baseline, prior to potential alteration 
of treatment and at completion of the exercise inter-
vention using dual- energy X- ray absorptiometry (DXA; 
Horizon A, Hologic, Waltham, Massachusetts, USA).45 In 
addition, body height and weight will be obtained using 
a digital measuring station (SECA 763; seca gmbh & co. 
kg., Hamburg, Germany) and waist and hip circumfer-
ence using a constant tension tape measure.
Quality of life and psychological health
The European Organization for Research and Treatment 
of Cancer (EORTC) Quality of Life Questionnaire Core 
module (QLQ- C30)46 and the pancreatic cancer specific 
module (QLQ- PAN26)47 will be used to assess QoL. To 
assess cancer- related fatigue, the EORTC QLQ- C30 with 
the addition of a validated 12- item fatigue module (QLQ- 
FA12) by the EORTC48 will be administered. Psycholog-
ical distress will be measured using the Brief Symptom 
Inventory-18.49 These questionnaires will be completed 
by participants at baseline, prior to potential alteration 
of treatment and at completion of the exercise interven-
tion. For participants who undergo PanCa surgery, they 
will also complete these questionnaires at 3 months post 
the exercise intervention.
Physical activity level
Self- reported physical activity level will be assessed using 
the Godin- Shephard Leisure- Time Physical Activity Ques-
tionnaire50 at baseline, prior to potential alteration of 
treatment and at completion of the exercise interven-
tion. For participants who receive PanCa surgery, they 
will also complete the questionnaire at 3 months post the 
exercise intervention.
Enjoyment of sport-related activities
To explore participants’ views on intermittent sport- 
related activities provided in the intervention, the inter-
vention group will be asked to complete a modified 
Physical Activity Enjoyment Scale (PACES)51 at comple-
tion of the exercise intervention.
Statistical analysis plans
Statistical analyses will be performed using SPSS 26.0 
(IBM, Chicago, Illinois, USA) and R V.4.0.2 (https://
www. r- project. org/). Descriptive statistics will be used for 
baseline demographic and clinical characteristics of each 
group. Categorical variables will be presented as frequen-
cies and proportions, and continuous variables will be 
presented as means and SDs (or medians and IQR). 
Between- group differences in baseline characteristics 
will be assessed using independent t- tests or the Mann- 
Whitney U test, as appropriate, for continuous data and 
the χ² test for categorical data.
The feasibility endpoints will be analysed descriptively 
and reported as frequencies and/or proportions. The 
differences between the intervention and control group 
in changes over time for efficacy outcomes (excluding 
LOS and PFS) will be assessed using linear mixed models 
or generalised linear mixed models with a random- effect 
factor for patients. Fixed- effect factors associated with 
secondary outcomes of interest include intervention 
assignment, time and an intervention by time interac-
tion as well as actually completed dosage of the exercise 
intervention and NAT. Analysis of LOS will be conducted 
using zero- truncated negative binomial regression. With 
regard to the analysis of PFS, the Kaplan- Meier method 
with log- rank test will be used. The number of partici-
pants with disease progression within the study period 
(ie, maximum 12 months) and the number of censored 
patients will be presented. In addition, the Cox propor-
tional hazards regression model will be used to estimate 
the hazard ratio between the study arms. The intention- 
to- treat principle will be applied to the efficacy outcomes 
analysis. The use of radiotherapy and choice of chemo-
therapy drugs in participants will be adjusted as potential 
confounding factors for the exercise intervention effects. 
All between- group differences will be reported using 
the 95% CI. Further analysis of the association between 
body composition and chemotherapy RDI at different 
time points will be performed using linear regression or 
generalised linear regression. Tests will be two- tailed and 
p≤0.05 will be considered statistically significant.
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Monitoring
Monitoring of the EXPAN trial will be performed 
through regular study progress reports review (6- month 
to 12- month intervals) by the ECU Research Ethics Team 
(RET) and the respective RET or Research Governance 
Office (RGO) for SCGH and SJOGSH. This is in line with 
the current Australian Code for the Responsible Conduct 
of Research.52 The research team of the EXPAN trial is 
also responsible for monitoring. A summary of exercise- 
related AEs (if any) will be provided to the participants’ 
treating oncologists every 4 weeks. If there is any indi-
cation that the exercise intervention is causing harm, a 
case- by- case analysis will be conducted by the research 
team before stopping or modifying the intervention for a 
participant. In addition, the research team will report to 
the RETs and RGOs immediately in the event of a serious 
AE (≥Grade 3 in the CTCAE).
ETHICS AND DISSEMINATION
Ethics approval
The research ethics of the EXPAN trial was reviewed 
and approved by the respective Human Research Ethics 
Committee at ECU (reference no.: 2020–02011- LUO) and 
the participating hospitals in Perth, Australia, including 
SCGH (reference no.: RGS 03956) and SJOGSH (refer-
ence no.: 1726). The trial was registered with the Austra-
lian New Zealand Clinical Trials Registry (ANZCTR) on 
20 October 2020 (ID: ACTRN12620001081909).
Protocol amendments
Any changes to the research protocol that may affect the 
conduct of the EXPAN trial, and the safety and poten-
tial benefits of participants (such as study design, eligi-
bility criteria, outcome measures and analysis methods) 
require a substantive protocol amendment. Such amend-
ment will be agreed on within the research team and 
communicated timely to the involved RET/RGO through 
their required review procedure, and approval will be 
obtained before implementation. In addition, protocol 
modifications will be tracked in the ANZCTR.
Confidentiality
On recruitment, each participant is assigned a unique 
identification number. During the trial, individually 
identifiable data/information will be deidentified with 
the number immediately after collection. As required 
by the ECU Data Management Plan, hard- copy records 
(eg, paper- based questionnaires) will be kept in a sepa-
rate lockable filing cabinet; digital data will be stored 
on a password- protected computer and uploaded to a 
SharePoint site that is exclusive to the EXPAN trial. All 
the study data/information will only be accessible to the 
study personnel. In accordance with the current Austra-
lian Code for the Responsible Conduct of Research,52 
the data/information collected for the EXPAN trial will 
be stored for at least 15 years following completion of 
the study. After the minimum storage duration, all study 
data/information will be permanently destroyed in an 
appropriate way.
Dissemination plan
Research outcomes of the EXPAN trial will be presented 
at national and international academic conferences and 
submitted for publication in peer- reviewed journals. In addi-
tion, to facilitate participant retention in the trial, a summary 
of individual results will be provided (on request) to those 
who complete the study. The report will outline individual 
results on body composition, muscle strength, functional 
capacity, psychological health and QoL at each time point 
and changes across all assessment time points.
DISCUSSION
The understanding of the role of exercise in patients 
with PanCa and in particular for those during NAT is 
limited due to their under representation in exercise 
oncology research. To date, there are only seven indi-
vidual published studies focusing exclusively on patients 
with PanCa.22–24 Of them, only three studies (all without 
control) have been conducted in patients during NAT 
(including one single- arm study,53 one case series25 
and one case report.26 In addition, among the ongoing 
exercise trials for patients with PanCa in  ClinicalTrial. 
gov, ANZCTR and CENTRAL, with the exception of 
the EXPAN trial, there is only one RCT over the course 
of preoperative therapy.54 In this context, additional 
rigorous research is required to support the use of exer-
cise in patients with PanCa undergoing NAT.
The EXPAN trial is designed to investigate primarily 
the feasibility of a supervised, multicomponent exercise 
medicine programme in patients with borderline resect-
able or locally advanced PanCa undergoing NAT. The 
study will also provide indications of efficacy of the inter-
vention on a wide range of clinical, physical and psycho-
social endpoints. This is the first randomised controlled 
exercise trial specifically for patients with PanCa in 
Australia and is a collaborative research project between 
EMRI- ECU and high- volume hospitals for PanCa in 
Western Australia (ie, SCGH and SJOGSH).
The EXPAN intervention takes into account common 
perceived barriers and facilitators to exercise in patients 
with PanCa. Qualitative and quantitative research in this 
patient group found that lack of motivation is among 
barriers to exercise, while a supportive environment and 
enjoyable activities may improve exercise uptake.55 56 To this 
end, an exercise intervention containing sport- related activ-
ities may be a potential strategy for the patients providing 
an interactive and enjoyable environment.57 As a result, a 
multicomponent programme consisting of clinical- based 
resistance and aerobic exercises and adapted sport activi-
ties will be adopted given the promising results in patients 
with PanCa undergoing NAT through a combined exercise 
programme.24 An exercise intervention of this format has 
recently been shown to be safe and effective in maintaining 
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physical activity for patients with sedentary breast cancer 
during adjuvant chemotherapy.58
Given the feasibility nature of the EXPAN trial, its results 
will be used to determine whether a subsequent fully 
powered RCT is needed. In addition, it will be an important 
basis for research into whether exercise can be implemented 
as a safe and efficacious component in a multidisciplinary 
management strategy for patients with PanCa or peripan-
creatic malignancies treated with comparable procedures 
(such as ampullary and periampullary).
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